Codex DNA Profit Margin

Codex DNA (DNAY) currently reports a profit margin of -231.23% as of September 2024. That compares with -164.83% in the prior-year period — down 40.3% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore Codex DNA's profit margin history and peer comparisons.

Codex DNA's profit margin decreased from -164.83% to -231.23% — a 40.3% year-over-year decrease (period ending September 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Codex DNA's profit margin of -231.23% is lower than the Healthcare sector average of 21.34%. That is roughly 1183.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Codex DNA's current -231.23% should be judged against Healthcare norms (sector average: 21.34%) and against DNAY's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -231.23%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for Codex DNA, and consider following DNAY for alerts when major investors trade the stock.